This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

When it comes to treating type 2 diabetes (T2D), more options are available to your patients than ever before. We need to look beyond metformin for many patients who are struggling to maintain glycemic control. This puts them at risk of long-term complications such as myocardial infarction, diabetic kidney disease or stroke.1–3

 

A shift in approach towards early intensification of treatment, as soon as it becomes necessary, could be all your patients need to reduce their HbA1c and reduce the risk factors that could lead to serious complications.3-5

Early and intensive hba1c
JBWO_SHIFT website icons - 7 out of 10

An early shift could change lives.
JBWO_SHIFT website icons - 90%

Is it time to shift the scale on T2D with weight loss?
JBWO_SHIFT website icons - #1

Could a multifactorial treatment approach help?

† In patients with HbA1c 7.0–7.9%. After at least 6 months on 2 oral glucose lowering medications.
uncontrolled hba1c
Reference not found
Reference not found

Reference not found

Reference not found
Reference not found
Overweight
Reference not found
Reference not found
Reference not found
ASCVD
Reference not found
people with T2D
Reference not found
image icon

image icon

Could a multifactorial approach
Reference not found
Reference not found

1.

Correa MF, Li Y, Kum H-C et al. Assessing the Effect of Clinical Inertia on Diabetes Outcomes: a Modeling Approach. J Gen Intern Med 2019;34:372–378.

2.

Paul SK, Klein K, Thorsted BL et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.

3.

Lind M, Imberg H, Coleman RL et al. Historical HbA1c, values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44(10):2231-2237.

4.

Burke GL, Bertoni AG, Shea S, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease. Archives of Internal Medicine. 2008;168(9):928.

5.

Mendis S, Puska P, Norrving B. Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization, Geneva 2011.

6.

Pantalone KM, Misra-Hebert AD, Hobbs TM et al. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care. 2018;41:e113-e114.

7.

Whitmore C. Type 2 diabetes and obesity in adults. Br J Nurs. 2010;19(14):880, 882-886.

8.

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016;133(24):2459-2502.

9.

Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-2786.

10.

Carls G, Huynh J, Tuttle E et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8(4):863-873.

11.

Mannucci E, Monami M, Dicembrini I et al. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. J Endocrinol Invest 2014;37:477–495.

12.

Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective Observational Study. BMI. 2000;321(7258):405-412.

13.

American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44:S7–S14.American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44:S7–S14.

14.

Khunti K, Wolden ML, Thorsted BL et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417

15.

UKPDS group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet.1998;352(9131):837–53.

16.

Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.

17.

Laiteerapong N Ham SA, Gao Y et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42:416–426.

18.

Del Prato S, Felton A-M, Munro N et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59:1345–1355.

19.

Abdul-Ghani M, Puckett C, Triplitt C et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17: 268–275.

20.

Desai U, NY Kirson NY, Kim J et al. Time to treatment intensification after monotherapy failure and its association with subsequent glycemic control among 93,515 patients with type 2 23 diabetes. Diabetes Care 2018; 41: 2096–2104.

21.

Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and The Obesity Society. Circulation. 2014;129(25 suppl 2):S102- S138.

22.

American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(suppl 1):S89-S97.

23.

Herrington W, Lacey B, Sherliker P, et al. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ Res 2016;118:535-546.

24.

National Institute of Health. Atherosclerosis. Updated March 24, 2022. Available at: https://www.nhlbi.nih.gov/health/atherosclerosis. Accessed June 2023.

25.

American Heart Association. Atherosclerotic Cardiovascular Disease (ASCVD). Available at: https://www.heart.org/en/professional/quality-improvement/ascvd. Accessed June 2023.

26.

Almdal T et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422–1426.

27.

Fox CS et al. Trends in cardiovascular complications of diabetes. JAMA 2004;292:2495–2499.

28.

Merz C et al. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol 2002;40:1877–1881.

29.

Perreault L, Boardman MK, Pak J. The Association Between Type 2 Diabetes and Cardiovascular Disease: The "For Your SweetHeart™" Survey. Adv Ther. 2019 Mar;36(3):746-755.

30.

Saeedi P, Karuranga S, Hammond L, Kaundal A, Malanda B, Prystupiuk M, Matos P. Cardiovascular diseases and risk factors knowledge and awareness in people with type 2 diabetes mellitus: a global evaluation. Diabetes Res Clin Pract. 2020 Jul;165:108194.

31.

An J, Nichols GA, Qian L, et al. Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes. BMJ Open Diab Res Care. 2021;9(1):e001847.

32.

Das SR, Everett BM, Birtcher KK, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117-1145.

33.

Fruchart J, Davignon J, Hermans MP, et al; Residual Risk Reduction Initiative (R3i). Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13(26):2-17.

34.

Shepherd J, Barter P, Carmena R, et al; Treating to New Targets Investigators. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care. 2006;29(6):1220-1226.

35.

Gæde P, Oellgaard J, Carstensen B et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298–307.

36.

Garber AJ Abrahamson MJ, Barzilay JI et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2016 Jan;22(1):84-113.

37.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20:508–19.

38.

Aronoff S, Berkowitz K, Shreiner B et al. Glucose Metabolism and Regulation: Beyond Insulin and Glucagon. Diabetes Spectr 2004;17(3):183–190.

39.

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740-756.

40.

Højberg PV, Vilsbøll T, Rabøl R et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199-207.

41

Kjems LL, Holst JJ, Vølund A et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380-386.

42.

Calanna S, Christensen M, Holst JJ et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56:965-972.

43.

Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-837.

44

Nauck MA & Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab 2018;20:5–21.

45.

Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202-210.

46.

Reed J, Bain S, Kanamarlapudi K et al. Recent advances in understanding the role of glucagon-like peptide 1. F1000Res. 2020 Apr 6;9:F1000 Faculty Rev-239.

47.

Muskiet MHA, Tonneijck L, Smits MM et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605–628.

48.

Sharma D, Verma S, Vaidya S et al. Recent updates on GLP-1 agonists: Current advancements & challenges. Biomed Pharmacother. 2018;108:952–962.

49.

Nauck MA & Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536.

50.

Andreasen CR, Andersen A, Knop FK et al. How glucagon-like peptide 1 receptor agonists work. Endocr Connect. 2021;10(7):R200–R212.

51.

Shaefer Jr CF, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818–826.

52.

Cornell SJ. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. Clin Pharm Ther. 2020;45(Suppl 1):17–27.

53.

Rasalam R, Barlow J, Kennedy M et al. GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective. Diabetes Ther. 2019;10(4):1205–1217.

54.

Kalra S, Das AK, Sahay RK et al. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Ther. 2019;10(5):1645–1717.

55.

Nauck MA Quast DR, Wefers J et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021;46:101102.

56.

Andrikou E, Tsioufis C, Andrikou I et al. GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic J Cardiol.2019;60(6):347–351.

57.

Sposito A, Berwanger O, de Carvalho LSF et al. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157.